Predictors of recurrence, early treatment failure and death from Staphylococcus aureus bacteraemia: observational analyses within the ARREST trial by Szubert, A et al.
ARTICLE IN PRESS 
JID: YJINF [m5G; August 13, 2019;16:44 ] 
Journal of Infection xxx (xxxx) xxx 
Contents lists available at ScienceDirect 
Journal of Infection 
journal homepage: www.elsevier.com/locate/jinf 
Predictors of recurrence, early treatment failure and death from 
Staphylococcus aureus bacteraemia: Observational analyses within the 
ARREST trial 
Alexander Szubert a , 1 , Sarah Lou Bailey b , f , 1 , Graham S. Cooke c , Tim Peto d , 
Martin J. Llewelyn e , Jonathan D. Edgeworth b , f , A. Sarah Walker a , d , 1 , Guy E. Thwaites d , g , 1 , ∗, 
on behalf of the United Kingdom Clinical Infection Research Group (UKCIRG) 2 
a Medical Research Council Clinical Trials Unit at University College London, University College London, UK 
b Guy’s and St. Thomas’ NHS Foundation Trust, London, UK 
c Imperial College London, UK 
d Centre for Tropical Medicine and Global Health, Nuﬃeld Department of Medicine, University of Oxford, UK 
e Brighton and Sussex Medical School, Brighton, UK 
f Kings College London, London, UK 
g Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam 
a r t i c l e i n f o 
Article history: 
Accepted 3 August 2019 
Available online xxx 
Keywords: 
Bacteraemia 
Staphylococcus aureus 
Mortality 
Recurrence 
Rifampicin 
s u m m a r y 
Objectives: Adjunctive rifampicin did not reduce failure/recurrence/death as a composite endpoint in the 
ARREST trial of Staphylococcus aureus bacteraemia, but did reduce recurrences. We investigated clinically- 
deﬁned 14-day treatment failure, and recurrence and S. aureus -attributed/unattributed mortality by 12- 
weeks to further deﬁne their predictors. 
Methods: A post-hoc exploratory analysis using competing risks models was conducted to identify sub- 
groups which might beneﬁt from rifampicin. A points-based recurrence risk score was developed and 
used to compare rifampicin’s beneﬁts. 
Results: Recurrence was strongly associated with liver and renal failure, diabetes and immune- 
suppressive drugs ( p < 0.005); in contrast, failure and S. aureus -attributed mortality were associated 
with older age and higher neutrophil counts. Higher SOFA scores predicted mortality; higher Charlson 
scores and deep-seated initial infection focus predicted failure. Unexpectedly, recurrence risk increased 
with increasing BMI in placebo ( p = 0.04) but not rifampicin ( p = 0.60) participants (p heterogeneity = 0.06). 
A persistent focus was judged the primary reason for recurrence in 23(74%). A 5-factor risk score based 
on BMI, Immunosuppression, Renal disease, Diabetes, Liver disease (BIRDL) strongly predicted recurrence 
( p < 0.001). 
Conclusions: Rifampicin reduces recurrences overall; those with greatest absolute risk reductions were 
identiﬁed using a simple risk score. Source control and adequate duration of antibiotic therapy remain 
essential to prevent recurrence and improve outcomes. 
© 2019 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
I
 
a  
w  
a  
p  
s  
a  
w
h
0
(ntroduction 
Bloodstream infection, or bacteraemia, caused by Staphylococcus
ureus ( S. aureus ) is a common, life-threatening infection world-
ide. 1 Numerous observational studies have documented its high∗ Corresponding author. 
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08.001 ssociated mortality (20–30%) and the frequent and serious com-
lications that arise from dissemination of bacteria by the blood-
tream. 2 These complications include deep-seated infections, such
s endocarditis and infections of bones, joints, and medical devices,
hich can recur if not treated effectively. 
Despite the frequency and severity of the complications of S.
ureus bacteraemia, few randomised controlled trials have been
onducted to deﬁne optimal antimicrobial therapy. 3 We recently
eported the results of the largest trial of antimicrobial treatment
4 ver conducted for S. aureus bacteraemia. ARREST randomised 758 
ion Association. This is an open access article under the CC BY-NC-ND license. 
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Fig. 1. Event rates over time from randomisation. Note: symbols indicate when 
events occurred. adults with S. aureus bacteraemia to receive standard antimicro-
bial therapy with either 2 weeks’ adjunctive rifampicin or placebo
to determine whether rifampicin reduced the incidence of treat-
ment failure at 14-days, infection recurrence, and death. After 12
weeks’ follow-up, rifampicin had no signiﬁcant effect on the com-
posite primary, or any secondary, eﬃcacy measures, including mor-
tality, duration of bacteraemia, and the development of rifampicin
resistance. Twenty planned and exploratory sub-group analyses of
the primary composite endpoint failed to identify a population
that unequivocally beneﬁtted from rifampicin. However, rifampicin
was associated with a small but signiﬁcant reduction in composite
endpoint components of bacteriologically-deﬁned and clinically-
deﬁned recurrence (number-needed-to-treat (NNT) to prevent one
recurrence 29 and 26 respectively). 
Given these relatively large recurrence NNT, and that rifampicin
had no effect on short-term or long-term mortality and substan-
tially complicated other treatment through drug-drug interactions,
we concluded that adjunctive rifampicin provided no overall
beneﬁt over standard antibiotic therapy in unselected adults with
S. aureus bacteraemia. Yet the inﬂuence of rifampicin on disease
recurrence remains intriguing. The trial offers a unique opportu-
nity to characterise the predictors of recurrence, 14-day failure
and attributable and non-attributable mortality from S. aureus
bacteraemia and to identify any sub-groups where the beneﬁts
of rifampicin on recurrence might be large enough to support
recommending its use. 
Materials and methods 
As previously described, 4,5 adult inpatients ( ≥18 years) with
S. aureus bacteraemia in 29 UK centres were eligible to enter the
ARREST trial (ISRCTN376 6 6216). Participants were randomised 1:1
to receive 2-weeks’ rifampicin versus placebo, plus standard ‘back-
bone’ antibiotic therapy chosen by the attending physician. Partic-
ipants were followed for 12-weeks. ARREST was approved by the
London (Westminster) Research Ethics Committee (12/LO/0637).
Participants, or their legal representatives (if incapacitated), gave
written informed consent. 
Endpoints 
Failure was deﬁned as symptoms and signs of infection ongoing
for > 14-days from randomisation, and recurrence as symptoms
and signs of infection after > 7-days of apparent clinical improve-
ment. Bacteriologically-deﬁned failure and recurrence required
S. aureus to be isolated from blood or another sterile site (e.g. joint
ﬂuid, pus from tissue). A structured clinical narrative for all poten-
tial clinical/bacteriological failures/recurrences was completed by
the site physician and all potential failures/recurrences and causes
of death were adjudicated by a blinded independent Endpoint
Review Committee (ERC) (Supplementary Methods). 4 
Statistical analysis 
To maximise statistical power we focussed on clinically-
deﬁned failure at 14-days and clinically-deﬁned recurrence by 12-
weeks, and separately considered S. aureus -attributed mortality
(ERC-adjudicated deﬁnitely/probably S. aureus -related) and non-
S. aureus -attributed mortality by 12-weeks, regardless of previous
failure/recurrence. Models for recurrence counted failure and death
without failure/recurrence as competing risks. 6 Mortality models
considered death from the other cause a competing risk. To esti-
mate continuously varying cause-speciﬁc event rates, we used ﬂex-
ible parametric models for the cause-speciﬁc hazards (Supplemen-
tary Methods). 7 Please cite this article as: A. Szubert, S.L. Bailey and G.S. Cooke et al.,
Staphylococcus aureus bacteraemia: Observational analyses within the A
08.001 Multivariate models 6 were based on backwards elimination
ith exit p = 0.1 to identify an exploratory model (but focussing
nterpretation on factors with p < 0.05), including non-linearity
y fractional polynomials where p ≤0.05, forcing randomised arm,
ender, age at randomisation, predominant focus of infection and
harlson co-morbidity score into models. Even given the trial’s
ize, the number of events was modest: however, given the lack of
vidence to date on predictors of recurrence and failure, we con-
idered all factors in Table 1 and Supplementary Table 1, excluding
hysician-determined factors (imaging and primary antibiotics). All
nalyses should therefore be considered exploratory. 
Initial variable selection was done on complete cases; ﬁnal
odels were re-ﬁtted to complete cases for the included factors.
nteractions with randomised arm were then considered; all in-
eractions with heterogeneity p ≤0.05 when considered individ-
ally were included together in the ﬁnal model. A points-based
isk score, where each predictor of recurrence is assigned a num-
er of points, and the higher an individual’s score the higher
heir recurrence risk, was then developed from model coeﬃcients, 8 
nd compared to a simpliﬁed score considering only factors with
trong model support ( p ≤0.005) and which substantially improved
he area under the receiver operating curve (AUROC). To explore
hether relative reductions in recurrence with rifampicin differed
y initial predicted risk, a model containing only the risk score,
andomised arm and their interaction was ﬁtted (Supplementary
ethods). Finally, the additional impact of imaging and primary
ntibiotic type, both determined by the physician, was evaluated. 
Predictors of 14-day failure were identiﬁed similarly using lo-
istic regression, excluding participants who died or experienced
ecurrence by 14-days to match the competing risks analyses of the
ther outcomes. Predictors of S. aureus -attributed mortality and
on- S. aureus attributed mortality were identiﬁed similarly using
ompeting risks methods. Analyses used Stata v15.1. 
esults 
Between December 2012 and October 2016, 758 eligible
articipants were randomised to add placebo ( n = 388) or ri-
ampicin ( n = 370) to their ‘backbone’ antibiotic treatment ( Table 1 ,
upplementary Table 1). 4 By 12-weeks, clinically-deﬁned fail-
re/recurrence or death occurred in 162 (21.4%) participants. There
ere 48 clinically-deﬁned 14-day failures (6.3% participants) and
1 clinically-deﬁned recurrences (4.1%); no participants were re-
orted to have experienced both failure and recurrence. As antici-
ated, most (90.3%) recurrences occurred after week-2 ( Fig. 1 ). 112 Predictors of recurrence, early treatment failure and death from 
RREST trial, Journal of Infection, https://doi.org/10.1016/j.jinf.2019. 
A
.
 Szu
b
ert,
 S.L.
 B
a
iley
 a
n
d
 G
.S.
 C
o
o
k
e
 et
 a
l.
 /
 Jo
u
rn
a
l
 o
f
 In
fectio
n
 xxx
 (xxxx)
 xxx
 
3
 
A
R
T
IC
L
E
 IN
 P
R
E
S
S
 
JID
:
 Y
JIN
F
 
[m
5
G
;
 A
u
g
u
st
 1
3
,
 2
0
1
9
;1
6
:4
4
 ]
 
Table 1 
Characteristics at randomisation of all participants in the trial and all those subsequently suffering recurrence, S. aureus attributed mortality, non- S. aureus attributed mortality and failure. 
Factor All participants 
N = 758 ∗ n (col%) 
or median (IQR) 
Recurrence N = 31 
(4.1%) n (row%) or 
median (IQR) 
Uni-variable 
p 
S. aureus -attributed 
mortality N = 56 
(7.4%) n (row%) or 
median (IQR) 
Uni-variable 
p 
Non- S. aureus 
attributed mortality 
N = 56 (7.4%) n (row%) 
or median (IQR) 
Uni-variable 
p 
Failure N = 48 
(6.3%) n (row%) or 
median (IQR) 
Uni-variable 
p 
Randomised arm 0.01 0.76 0.70 0.95 
Rifampicin 370 (48.8%) 8 (2.2%) 28 (7.6%) 28 (7.6%) 23 (6.2%) 
Placebo 388 (51.2%) 23 (5.9%) 28 (7.2%) 28 (7.2%) 25 (6.4%) 
Male 495 (65.3%) 21 (4.2%) 0.77 38 (7.7%) 0.67 35 (7.1%) 0.62 29 (5.9%) 0.50 
Age at last birthday (years) 65 (50, 76) 58 (47, 75) 0.27 79 (73, 84) < 0.0001 76 (67, 85) < 0.0001 74 (64, 80) 0.001 
BMI (kg/m 2 ) 26.3 (22.6, 31.1) 28.1 (24.9, 34.9) 0.05 24.7 (21.5, 27.4) 0.006 24.9 (22.1, 30.1) 0.08 25.6 (21.6, 28.9) 0.20 
Charlson comorbidity score ∗ 2 (0, 3) 2 (1, 3) 0.27 2 (1, 4) 0.03 3 (1, 6) < 0.0001 2 (1, 4) 0.07 
SOFA score ∗ 2 (1, 4) 2 (1, 4) 0.77 3 (2, 6) 0.0002 4 (2, 5) 0.001 3 (1, 4.5) 0.13 
MRSA 47 (6.2%) 1 (2.1%) 0.47 4 (8.5%) 0.80 5 (10.6%) 0.43 4 (8.5%) 0.52 
Initial infection focus ∗ , † 0.81 0.12 0.94 0.0002 
Deep-seated 301 (39.7%) 14 (4.7%) 24 (8.0%) 20 (6.6%) 38 (12.6%) 
Native heart valve 33 (4.4%) 1 (3.0%) 5 (15.2%) 1 (3.0%) 4 (12.1%) 
Osteoarticular ∗∗ 133 (17.5%) 7 (5.3%) 10 (7.5%) 9 (6.8%) 17 (12.8%) 
Deep tissue infection/abscess 
(including brain 
infection)/epidural/intraspinal 
empyema/infected intravascular 
thrombus 
88 (11.6%) 3 (3.4%) 6 (6.8%) 7 (8.0%) 9 (10.2%) 
Prosthetic heart 
valve/joint/implanted vascular 
device 
47 (6.2%) 3 (6.4%) 3 (6.4%) 3 (6.4%) 8 (17.0%) 
Superﬁcial 323 (42.6%) 12 (3.7%) 17 (5.3%) 24 (7.4%) 8 (2.5%) 
Central/peripheral venous line 125 (16.5%) 7 (5.6%) 1 (0.8%) 9 (7.2%) 0 (0.0%) 
Skin/soft tissue/surgical 
wound/pneumonia 
198 (26.1%) 5 (2.5%) 16 (8.1%) 15 (7.6%) 8 (4.0%) 
Not established 133 (17.5%) 5 (3.8%) 15 (11.3%) 12 (9.0%) 2 (1.5%) 
Speciﬁc comorbidities 
Cancer ∗ 129 (17.0%) 1 (0.8%) 0.07 10 (7.8%) 0.82 16 (12.4%) 0.02 6 (4.7%) 0.43 
Immunosuppressed ∗ , ‡ 62 (8.2%) 6 (9.7%) 0.02 1 (1.6%) 0.11 5 (8.1%) 0.80 5 (8.1%) 0.57 
Chronic lung disease ( N = 756) 90 (11.9%) 5 (5.6%) 0.47 10 (11.1%) 0.14 11 (12.2%) 
( N = 55) 
0.05 10 (11.1%) 0.05 
Renal disease ∗ 0.003 0.003 0.32 0.0004 
No 612 (80.8%) 19 (3.1%) 43 (7.0%) 41 (6.7%) 34 (5.6%) 
Moderate or severe 70 (9.2%) 3 (4.3%) 12 (17.1%) 8 (11.4%) 12 (17.1%) 
End stage (requiring dialysis) 75 (9.9%) 9 (12.0%) 1 (1.3%) 7 (9.3%) 2 (2.7%) 
Liver disease ( N = 755) ∗ 56 (7.4%) 8 (14.3%) 0.0002 4 (7.1%) 0.91 2 (3.6%) 0.25 4 (7.1%) 0.77 
Diabetes ∗ 228 (30.1%) 15 (6.6%) 0.03 17 (7.5%) 0.99 16 (7.0%) 0.74 17 (7.5%) 0.40 
Time from ﬁrst new symptom caused 
by S. aureus to starting antibiotics 
(days) ( N = 754) 
1 (0, 3) 2 (1, 4) 0.22 1 (0, 2.5) 0.30 1 (0, 2) 0.14 2 (0, 5) 0.54 
Time from admission to positive blood 
culture (days) 
0 (0, 1) 0 (0, 0) 0.04 0 (0, 1) 0.76 0 (0, 6) 0.12 0 (0, 1) 0.43 
Note: showing n(% of row) for categorical factors, or median (IQR) for continuous factors. p-values from competing risks regression (recurrence, S. aureus -attributed mortality, non- S. aureus attributed mortality) or logistic 
regression (failure). 
∗ One participant withdrew shortly after randomisation without an enrolment form having been completed: most baseline characteristics (indicated with ∗) are therefore missing for this one participant. If any other participants 
had missing data, then denominators are shown. 
† Individuals could have multiple foci, in which case the predominant focus is given, deﬁned by the following order: native heart valve > native joint/vertebral bone/disc > deep tissue infection/abscess/epidural/intraspinal 
empyema/infected intravascular thrombus > prosthetic heart valve/joint/implanted vascular device > central/peripheral venous line > skin/soft tissue/surgical wound/pneumonia. 
∗∗ Includes any native joint/vertebral bone/disc/other bone infection. 
‡ Systemic corticosteroid therapy, neutropenia, currently receiving immune suppressive therapy (excluding anti-neoplastic chemotherapy), organ or marrow transplant, or living with HIV. 
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Table 2 
Characteristics of recurrences. 
Placebo N = 23 Rifampicin N = 8 Total N = 31 
Focus at initial episode ∗ Central venous line (including picc line) 5 (22%) 2 (25%) 7 (23%) 
Implanted vascular device 4 (17%) 0 (0%) 4 (13%) 
Native heart valve 1 (4%) 0 (0%) 1 (3%) 
Native joint 1 (4%) 1 (13%) 2 (6%) 
Vertebral bone/disc 3 (13%) 3 (38%) 6 (19%) 
Epidural or intraspinal empyema 1 (4%) 0 (0%) 1 (3%) 
Deep tissue infection or abscess 1 (4%) 3 (38%) 4 (13%) 
Surgical wound 2 (9%) 0 (0%) 2 (6%) 
Skin/soft tissue (excluding wounds) 6 (26%) 1 (13%) 7 (23%) 
Pneumonia 1 (4%) 0 (0%) 1 (3%) 
Not established 4 (17%) 1 (13%) 5 (16%) 
Focus at recurrence ∗ Central venous line (including picc line) 3 (13%) 1 (13%) 4 (13%) 
Implanted vascular device 5 (22%) 0 (0%) 5 (16%) 
Native heart valve 1 (4%) 0 (0%) 1 (3%) 
Native joint 0 (0%) 2 (25%) 2 (6%) 
Vertebral bone/disc 5 (22%) 5 (63%) 10 (32%) 
Epidural or intraspinal empyema 1 (4%) 0 (0%) 1 (3%) 
Other bone 2 (9%) 0 (0%) 2 (6%) 
Deep tissue infection or abscess 3 (13%) 3 (38%) 6 (19%) 
Skin/soft tissue (excluding wounds) 4 (17%) 1 (13%) 5 (16%) 
Not established 4 (17%) 0 (0%) 4 (13%) 
Median days between symptoms relating to ﬁrst bacteraemia and starting antibiotics 
(IQR) 
1.0 (2.0, 3.0) 1.0 (3.0, 6.5) 2.0 (1.0, 4.0) 
Median days between ﬁrst positive culture and recurrence (IQR) 46 (29, 58) 48 (33, 67) 46 (29, 58) 
Median BMI (IQR) kg/m 2 28.1 (25.1, 40.1) 27.2 (23.1, 29.5) 28.1 (24.9, 34.9) 
Source control during 
initial episode? 
Complete 5 (22%) 1 (13%) 6 (19%) 
Partial 2 (9%) 0 (0%) 2 (6%) 
No 13 (57%) 7 (88%) 20 (65%) 
Unknown source 3 (13%) 0 (0%) 3 (10%) 
If complete/partial source control, median days from ﬁrst positive culture to source 
removal (IQR) ( N = 6 † ) 
3 (1, 3) 2 (2, 2) 3 (1, 3) 
On antibiotics at recurrence? 5 (22%) 6 (75%) 11 (35%) 
If no, median days between stopping antibiotics and recurrence (IQR) 25.5 (9.0, 35.0) 31.0 (30.0, 32.0) 29.5 (11.0, 34.5) 
Backbone antibiotic 
prescribed during initial 
episode until date of 
recurrence ∗∗
Cefazolin 1 (4%) 0 (0%) 1 (3%) 
Ceftriaxone 2 (9%) 1 (13%) 3 (10%) 
Clindamycin 0 (0%) 1 (13%) 1 (3%) 
Co-amoxiclavulante 1 (4%) 0 (0%) 1 (3%) 
Daptomycin 2 (9%) 0 (0%) 2 (6%) 
Flucloxacillin 19 (83%) 6 (75%) 25 (81%) 
Levoﬂoxacin 1 (4%) 0 (0%) 1 (3%) 
Meropenem 1 (4%) 0 (0%) 1 (3%) 
Teicoplanin 1 (4%) 1 (12%) 2 (6%) 
Vancomycin 1 (4%) 2 (25%) 3 (10%) 
Median total days ‡ on backbone antibiotic (IQR) 18.0 (15.0, 29.0) 30.5 (18.5, 45.0) 19.0 (15.0, 31.0) 
Focus identiﬁed and 
conﬁrmed during initial 
episode? 
Yes 13 (57%) 6 (75%) 19 (61%) 
Partially 1 (4%) 0 (0%) 1 (3%) 
No 9 (39%) 2 (25%) 11 (35%) 
Focus changed between 
initial episode and 
recurrence? 
Yes 6 (26%) 2 (25%) 8 (26%) 
Partially 2 (9%) 3 (38%) 5 (16%) 
No 8 (35%) 2 (25%) 10 (32%) 
Not established on one or both episodes 7 (30%) 1 (13%) 8 (26%) 
Recurrence conﬁrmed bacteriologically? 15 (65%) 3 (38%) 18 (58%) 
Level of certainty of 
recurrence 
Deﬁnite 18 (78%) 6 (75%) 24 (77%) 
Probable 2 (9%) 2 (25%) 4 (13%) 
Possible 3 (13%) 0 (0%) 3 (10%) 
Factors leading to 
recurrence 
Probably failure of antibiotic treatment 2 (9%) 1 (13%) 3 (10%) 
Probably failure of source management (source 
not recognised) 
10 (43%) 2 (25%) 12 (39%) 
Probably failure of source management (source 
recognised, not actively managed) 
4 (17%) 3 (38%) 7 (23%) 
Probably failure of source management (source 
recognised, actively managed) 
3 (13%) 1 (13%) 4 (13%) 
Not possible to distinguish whether antibiotic or 
source management failure 
4 (17%) 1 (13%) 5 (16%) 
Note: showing n(%) or median (IQR). 
∗ % of participants with focus. Some participants have multiple foci so totals are > 100%. 
† The other one participant with complete/partial source control had a focus of infection of skin/soft tissue. Therefore source removal not applicable. 
∗∗ % of participants prescribed antibiotic. Some participants had different backbone antibiotics at different times and therefore more than one backbone antibiotic overall, 
so totals are > 100%. 
‡ Median days on backbone antibiotic, or for participants who had multiple sequential backbone antibiotics, median of the sum of days on all backbone antibiotics. 
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Fig. 2. Effect of BMI on recurrence by randomised arm. Note: sHR = subhazard ratio. 
Filled circles show BMI values where recurrences occurred; points show other BMI 
values where recurrence did not occur. 14.8%) participants died by 12-weeks. S. aureus -attributed mortal-
ty was more common than non- S. aureus attributed mortality until
ay-21, with only six non- S. aureus attributed-deaths before day-14
 Fig. 1 ). 
ecurrence descriptions and predictors 
Of 31 participants experiencing recurrences (8 rifampicin ver-
us 23 placebo; p = 0.01), 5(63%) rifampicin versus 9(39%) placebo
ad a deep focus at the initial infection episode ( p = 0.41; 40%
eep focus overall), but 7(88%) versus 13(57%) respectively had a
eep focus at recurrence ( Table 2 ; Supplementary Table 2). The re-
urrence infection focus was vertebral bone/disc in 10(32%) recur-
ences, compared with 69/758 (9%) initial episodes, and differed
rom the initial episode in 8(26%) recurrences, with similar propor-
ions in the randomised arms. Recurrence was conﬁrmed bacteri-
logically in 15(65%) placebo versus 3(38%) rifampicin participants
 p = 0.23). The choice of initial backbone antibiotic treatment was
imilar between the arms, with most (81%) receiving ﬂucloxacillin.
owever, 6(75%) rifampicin versus 5(22%) placebo remained on an-
ibiotics at recurrence ( p = 0.01). The median time on antibiotics
re-recurrence was 31 versus 18 days respectively ( p = 0.11) and
etween ﬁrst positive culture and recurrence 48 versus 46 days re-
pectively ( p = 0.64). 
Overall, only 8(26%) participants with recurrence achieved com-
lete/partial source control of the initial infection (1(13%) ri-
ampicin versus 7(30%) placebo; p = 0.64). Recurrence was adjudi-
ated by the ERC to result from antibiotic treatment failure alone
n just 3(10%) participants (one rifampicin, two placebo). The main
actor leading to recurrence for 23(74%) of participants was consid-
red a failure of source management, including 12(39%) where the
ource was not recognised. 
Of the 31 participants with recurrences, nine (29%) died post-
ecurrence (1/8 (13%) rifampicin versus 8/23 (35%) placebo; log-
ank p = 0.19). Six deaths occurred by 12-weeks; of these, ﬁve were
. aureus -attributed (one rifampicin, four placebo) and one non- S.
ureus attributed (placebo; pneumonia and renal failure). 
Final multivariable models included 733 participants of whom
1(4.2%) experienced recurrence. Recurrence was less common
ith adjunctive rifampicin (overall rifampicin vs placebo p = 0.001;
able 3 ) (as in 4 ). Most striking was that recurrence was indepen-
ently more common in participants with speciﬁc comorbidities
namely liver and renal disease, diabetes and those with immuno-
uppression/receiving immune suppressive drugs, all p < 0.005).
harlson and SOFA scores were modestly higher in participants
ith any of these speciﬁc co-morbidities (median (IQR) 3 (2–4)
nd 3 (1–5) respectively, versus 0 (0–2) and 2 (1–3) respectively
n those without any of them, p < 0.0 0 01 and p = 0.0 0 01 re-
pectively). However, whilst univariably neither Charlson ( p = 0.27)
or SOFA ( p = 0.77) scores were associated with recurrence, af-
er adjusting for other factors, higher Charlson ( p = 0.009) and
OFA ( p = 0.02) scores independently reduced recurrence risk,
hether participants had these speciﬁc co-morbidities or not
p heterogeneity > 0.6). This adjusted association with Charlson was
riven by inclusion of renal disease and diabetes; and with SOFA
y renal disease. 
4-day failure predictors 
14-day failure was independently more common in older par-
icipants ( p = 0.006) and those with higher neutrophil counts
 p = 0.02) or Charlson scores ( p = 0.02) ( Table 3 ). Initial predom-
nant focus was also associated with failure ( p = 0.001), which
as lowest in those with central/peripheral lines or unestab-
ished foci, and highest in those with deep foci. Failure wasPlease cite this article as: A. Szubert, S.L. Bailey and G.S. Cooke et al.,
Staphylococcus aureus bacteraemia: Observational analyses within the A
08.001 ndependently more common in those with a longer time be-
ween ﬁrst new symptom caused by S. aureus and starting an-
ibiotics ( p = 0.05; Supplementary Fig. 1(b)) or shorter time be-
ween positive blood culture and starting antibiotics at base-
ine ( p = 0.01). There was no effect of rifampicin ( p = 0.68),
ender ( p = 0.41) or any other factor ( p > 0.1) and no in-
eractions with randomised arm (p heterogeneity > 0.1). A model
ontaining C-reactive protein (CRP) instead of neutrophils was sim-
larly predictive (Akaike Information Criterion (AIC) = 309 vs origi-
al 306), but neutrophils was more predictive than CRP in a model
ontaining both ( p = 0.03 and p = 0.23 respectively). 
ortality predictors 
Overall, S. aureus -attributed mortality was independently higher
n participants who were older ( p < 0.0 0 01), with higher neu-
rophil counts ( p = 0.001) or SOFA score ( p = 0.005) ( Table 3 ). Sim-
larly S. aureus unattributed mortality was independently more
ommon in participants who were older ( p < 0.0 0 01), with
igher Charlson ( p = 0.003) or SOFA ( p = 0.01) scores. There was
o effect of rifampicin, focus of infection, gender or any other
actor ( p > 0.1) and no interactions with randomised arm
p heterogeneity > 0.05) for either S. aureus -attributed or unattributed
ortality. 
xploratory sub-group analysis of rifampicin effect on recurrence and 
oints-based recurrence risk score 
Overall, there was no evidence that the overall signiﬁcant
elative effect of rifampicin upon recurrence differed by focus
f infection categorised as deep-seated vs. other/not established
p heterogeneity = 0.16), or deep-seated vs. other vs. not established
p heterogeneity = 0.37). However, considering focus separately, af-
er adjusting for other factors, there was some evidence that, in
ontrast to other participants, rifampicin did not reduce recur-
ences in those with an initial native joint/vertebral bone/disc fo-
us (p heterogeneity = 0.03, Table 3 ) (unadjusted results in Table 4 ).
nterestingly, there was also some evidence that recurrence risk in-
reased with increasing BMI in placebo ( p = 0.04), but did not de-
end on BMI in rifampicin ( p = 0.60; p heterogeneity = 0.06) ( Table 3 ,
ig. 2 ). 
To identify patients who might beneﬁt most from rifampicin
n terms of absolute recurrence risks, we developed a points-
ased risk score for recurrence from the competing-risks regres-
ion model in Table 3 . The full linear predictor had AUROC = 0.84 Predictors of recurrence, early treatment failure and death from 
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Table 3 
Independent baseline predictors of recurrence, S. aureus -attributed mortality, non- S. aureus attributed mortality and failure. 
Recurrence ( N = 733) S. aureus -attributed mortality 
( N = 731) 
Non- S. aureus attributed 
mortality ( N = 757) 
Failure ( N = 707) 
sHR [95% CI] P sHR [95% CI] P sHR [95% CI] p OR [95% CI] P 
Rifampicin vs placebo where no 
interaction effects 
– – 1.21 [0.66–2.19] 0.54 1.26 [0.73–2.19] 0.41 1.14 [0.61–2.15] 0.68 
Rifampicin vs placebo if BMI 
25 kg/m 2 and focus of infection 
not native joint/vertebral 
bone/disc/other bone 
0.23 [0.07–0.71] 0.01 – – – – – –
BMI: overall per kg/m 2 higher – – 0.95 [0.89–1.01] 0.08 – – – –
Per kg/m 2 higher in rifampicin 0.98 [0.89–1.07] 0.60 – – – – – –
Per kg/m 2 higher in placebo 1.09 [1.00–1.19] 0.04 – – – – – –
Heterogeneity 0.06 – – –
Overall rifampicin vs placebo 
(incorporating interaction effects) 
0.001 – – –
Gender, female vs male 0.87 [0.37–2.03] 0.74 0.68 [0.36–1.31] 0.25 1.23 [0.70–2.16] 0.46 1.33 [0.68–2.60] 0.41 
Age (per 10 years older) 1.18 [0.88–1.57] 0.27 1.72 [1.33–2.23] < 0.0001 1.55 [1.28–1.89] < 0.0001 1.35 [1.09–1.68] 0.006 
Charlson score (per unit higher) 0.56 [0.36–0.87] 0.009 1.12 [0.99–1.28] 0.08 1.19 [1.06–1.34] 0.003 1.17 [1.02–1.35] 0.02 
SOFA score (per unit higher) 0.76 [0.61–0.96] 0.02 1.17 [1.05–1.31] 0.005 1.13 [1.03–1.24] 0.01 – –
Neutrophil count (per 10 9 /L higher) – – 1.08 [1.03–1.13] 0.001 – – 1.07 [1.01–1.12] 0.02 
Predominant focus of infection, vs. 
skin/soft tissue/surgical 
wound/pneumonia 
– 0.25 0.90 0.001 
Native heart valve 1.85 [0.16–20.9] 0.62 2.15 [0.59–7.80] 0.24 0.48 [0.06–3.63] 0.48 3.76 [1.00–14.1] 0.05 
Native joint/vertebral 
bone/disc/other bone 
0.64 [0.15–2.76] ∗ 0.55 1.14 [0.46–2.85] 0.77 1.12 [0.49–2.56] 0.79 3.25 [1.30–8.14] 0.01 
Deep tissue infection/abscess 
(including brain infection)/ 
epidural/intraspinal 
empyema/infected 
intravascular thrombus 
0.83 [0.18–3.97] 0.82 1.29 [0.47–3.54] 0.62 1.42 [0.59–3.44] 0.44 2.69 [0.95–7.62] 0.06 
Prosthetic heart valve/joint/ 
Implanted vascular device 
1.15 [0.22–5.95] 0.87 0.57 [0.16–2.01] 0.38 0.62 [0.17–2.21] 0.46 3.72 [1.23–11.2] 0.02 
Central/peripheral venous line 1.75 [0.48–6.47] 0.40 0.15 [0.02–1.18] 0.07 0.97 [0.40–2.32] 0.94 0.19 [0.04–0.93] ∗∗∗ 0.04 
Not established 1.38 [0.34–5.56] 0.65 1.49 [0.67–3.31] 0.32 1.19 [0.54–2.61] 0.67 0.19 [0.04–0.93] ∗∗∗ 0.04 
Renal disease, vs. no < 0.0001 – – – – –
Moderate or severe 6.52 [0.70–60.9] 0.1002 – – – – – –
End stage (requiring dialysis) 25.2 [5.89–107.4] < 0.0001 – – – – – –
Liver disease, yes vs no 14.2 [4.08–49.7] < 0.0001 – – – – – –
Chronic lung disease, yes vs no 2.43 [0.65–9.05] 0.19 ∗∗ – – – – – –
Diabetes, yes vs no 5.06 [1.77–14.5] 0.002 – – – – – –
Immunosuppressed, yes vs no 4.78 [1.97–11.6] 0.001 – – – – – –
Time from ﬁrst new symptom 
caused by S. aureus to starting 
antibiotics (per day longer) 
Suppl. Fig. 1 (a) 0.007 – – – – Suppl. Fig. 1 (b) 0.05 
Time from admission to positive 
blood culture (per day longer) 
0.86 [0.75–0.98] 0.02 – – – – – –
Time from positive blood culture to 
starting antibiotics (per day 
longer) 
– – – – – – 0.55 [0.35–0.89] 0.01 
Note: sHR = subhazard ratio. OR = odds ratio. Adjusted for other factors in column. 
∗ Effect in placebo. Effect in rifampicin: sHR = 4.76 [1.12, 20.34] p = 0.04. Heterogeneity p = 0.03. 
∗∗ p = 0.094 before interactions added; p = 0.19 in ﬁnal model including interactions. 
∗∗∗ Central/peripheral venous line and not established combined as no participants with a focus of central/peripheral venous line experienced failure therefore combined 
with category with next lowest risk ( Table 1 ). 
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i  [95% CI 0.77–0.92] for predicting recurrence in the placebo arm. A
score based on all factors in this model (Supplementary Table 3)
ranged from 1–80, had AUROC = 0.81 [0.72–0.91], good calibration
(Hosmer–Lemeshow p = 0.70), and strongly predicted recurrence
(unadjusted sHR = 1.20 per point higher [1.14–1.27] p < 0.001).
There was no evidence that rifampicin’s relative beneﬁts differed
by initial risk score (p heterogeneity = 0.30), but absolute beneﬁts var-
ied substantially (Supplementary Table 4, Supplementary Fig. 2). 
A simpliﬁed risk score based on ﬁve key factors ( B MI,
I mmunosuppression, R enal disease, D iabetes, L iver disease
( BIRDL ), Table 5 ) ranged from 0–8, with AUROC = 0.74 [95% CI
0.63–0.85], good calibration (Hosmer–Lemeshow p = 0.95), and
also strongly predicted recurrence (unadjusted sHR = 1.84 per
point higher [1.49–2.26] p < 0.001) with no evidence of het-
erogeneity in rifampicin’s relative beneﬁts (p heterogeneity = 0.76).Please cite this article as: A. Szubert, S.L. Bailey and G.S. Cooke et al.,
Staphylococcus aureus bacteraemia: Observational analyses within the A
08.001 owever, because the absolute recurrence risk varied strongly by
he BIRDL risk score ( Fig. 3 , Supplementary Table 5), number-
eeded-to-treat (NNT) with rifampicin to prevent one recurrence
as under 12 for the 109/737 (14.8%) participants with BIRDL
cores ≥3. In those with BIRDL ≥3, rifampicin was not associated
ith increased SAEs ( p = 0.57) or grade 3/4 AEs ( p = 0.42). 
iscussion 
S. aureus bacteraemia is a serious and diﬃcult to treat infection,
rimarily because the bacteria can disseminate to form deep infec-
ion foci that are easily missed and often require surgical drainage
nd prolonged antimicrobial therapy to cure. Early treatment fail-
re, recurrence, and death are common and reported respectively
n around 10%, 5%, and 20% of those affected. 2 , 9–12 Previous stud- Predictors of recurrence, early treatment failure and death from 
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Table 4 
Recurrences, S. aureus -attributed deaths, non- S. aureus attributed deaths and failures by randomised arm and predominant focus of infection. 
Predominant infection focus Recurrence S. aureus -attributed death Non- S. aureus attributed death Failure 
Placebo Rifampicin Placebo Rifampicin Placebo Rifampicin Placebo Rifampicin 
N = 388 N = 370 N = 388 N = 370 N = 388 N = 370 N = 388 N = 370 
Native heart valve 1/16 (6%) 0/17 (0%) 4/16 (25%) 1/17 (6%) 1/16 (7%) 0/17 (0%) 4/16 (25%) 0/17 (0%) 
Native joint/vertebral bone/disc/other 
bone 
3/71 (4%) 4/62 (6%) 5/71 (7%) 5/62 (8%) 5/71 (7%) 4/62 (6%) 7/71 (10%) 10/62 (16%) 
Deep tissue infection/abscess (including 
brain infection)/epidural/intraspinal 
empyema/infected intravascular 
thrombus 
2/46 (4%) 1/42 (2%) 3/46 (7%) 3/42 (7%) 4/46 (9%) 3/42 (7%) 6/46 (13%) 3/42 (7%) 
Prosthetic heart valve/joint/implanted 
vascular device 
3/26 (12%) 0/21 (0%) 0/26 (0%) 3/21 (14%) 3/26 (12%) 0/21 (0%) 4/26 (15%) 4/21 (19%) 
Central/peripheral venous line 5/65 (8%) 2/60 (3%) 0/65 (0%) 1/60 (2%) 4/65 (6%) 5/60 (8%) 0/65 (0%) 0/60 (0%) 
Skin/soft tissue/surgical 
wound/pneumonia 
5/98 (5%) 0/100 (0%) 8/98 (8%) 8/100 (8%) 8/98 (8%) 7/100 (7%) 3/98 (3%) 5/100 (5%) 
Not established 4/66 (6%) 1/68 (1%) 8/66 (12%) 7/68 (10%) 3/66 (5%) 9/68 (13%) 1/66 (2%) 1/68 (2%) 
Note: showing n events/n with focus (%), unadjusted, i.e. not accounting for associations in Table 3 . Individuals could have multiple foci, in which case they are included 
under the predominant category (native heart valve > native joint/vertebral bone/disc > deep tissue infection/abscess/epidural/intraspinal empyema/infected intravascular 
thrombus > prosthetic heart valve/joint/implanted vascular device > central/peripheral venous line > skin/soft tissue/surgical wound/pneumonia). 
Table 5 
Simpliﬁed recurrence risk score (BIRDL). 
Factor Score value given 
if present 
Minimum possible 
value for score 
Maximum possible 
value for score 
B MI (kg/m 2 ) 0 2 
≤30 0 
> 30–40 1 
> 40 2 
I mmunosuppressed ∗ 1 0 1 
R enal disease † 0 2 
No 0 
Moderate or severe 1 
End stage (requiring dialysis) 2 
D iabetes † 1 0 1 
L iver disease † 2 0 2 
Total 0 8 
For example, a patient with BMI 22, end stage renal disease and diabetes would have recurrence risk 
score = 0 + 0 + 2 + 1 + 0 = 3. 
∗ Systemic corticosteroid therapy, neutropenia, currently receiving immune suppressive therapy (ex- 
cluding anti-neoplastic chemotherapy), organ or marrow transplant, or living with HIV. 
† Renal disease and mild (including chronic hepatitis), moderate or severe liver disease deﬁned as for 
the Charlson comorbidity index. Diabetes includes that with (as per Charlson) or without end-organ dam- 
age. End stage renal disease deﬁned as requiring either peritoneal dialysis or haemodialysis. 
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c  es have concluded that these outcomes are more common in the
lderly with comorbidities, if initial antimicrobial therapy is inad-
quate, if bacteraemia is prolonged, and if the focus of infection
s either not established or is deep-seated and not drained or re-
oved. 2 , 9–12 However, there are limited high-quality data that can
e used to investigate the individual predictors of these outcomes
nd almost none from large, randomised trials of antimicrobial in-
erventions hypothesised to reduce them. 
The ARREST trial provides a unique opportunity to better un-
erstand the determinants of poor outcome from S. aureus bac-
eraemia. 4 Further characterisation of the 31 recurrences revealed
hat 32% were associated with vertebral bone/disc infection when
ecurrence occurred. Numbers were small, but preceding the re-
urrence, placebo participants were somewhat less likely to have
n initial deep infection focus, were less likely to be on antibi-
tics at the time of recurrence, and had recurrences that were
ore likely to be bacteriologically-conﬁrmed than rifampicin par-
icipants. These ﬁndings suggest rifampicin may enhance bacterial
illing and sterilisation of less complicated infections, 13 rather than
hose with deep foci, and that short antibiotic courses may in-
rease recurrence risk. However, the blinded ERC adjudicated that
ailure to identify and control the initial focus, rather than inade-Please cite this article as: A. Szubert, S.L. Bailey and G.S. Cooke et al.,
Staphylococcus aureus bacteraemia: Observational analyses within the A
08.001 uate antibiotic treatment, was the main factor behind 75% of re-
urrences, regardless of whether or not rifampicin was given. 
Comparing the baseline predictors of recurrence, failure and
eath suggests there may be biological and clinical differences
etween these outcomes. Unlike 14-day failure and S. aureus-
ttributed/unattributed mortality, recurrence was not associated 
ith age, total Charlson score or initial disease severity (assessed
y SOFA score or blood neutrophils), but was strongly associated
ith speciﬁc comorbidities associated with immune dysfunction
liver and renal failure, diabetes and immunosuppression/receiving
mmune suppressive drugs). Other case-series have reported a sim-
lar increased risk of recurrence following S. aureus bacteraemia in
hose with impaired immunity. 11,14,15 14-day failure was associated
ith initial infection focus, being less likely in those whose focus
as not established or was an infected intravenous catheter, and
ore likely in those with endocarditis, or osteoarticular or medi-
al device infections. 
Initial infection focus had relatively little inﬂuence on ri-
ampicin’s effect on recurrence. In particular, a deep infection focus
id not predict recurrence and there was no evidence rifampicin
eneﬁtted the treatment of these infections, especially if the fo-
us was not controlled by drainage or removal. Intriguingly, high Predictors of recurrence, early treatment failure and death from 
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Fig. 3. Distribution of BIRDL score and associated recurrence risk and NNT. 
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 BMI appeared to predict recurrence in the placebo but not the ri-
fampicin arm ( Fig. 2 ), which might be explained by differences in
the ability to identify and drain/remove infection foci, or possible
under-dosing, in those with high BMI. Additional pharmacokinetic
studies are planned to address the latter hypothesis. 
Given the importance of recurrence as an outcome from S.
aureus bacteraemia we created a simple points-based risk score
( BIRDL : B MI, I mmunosuppression, R enal disease, D iabetes, L iver
disease) which was highly predictive of recurrence. The score re-
quires validation in different populations, but could form the basis
for better identifying high-risk patients. Whilst we were unable to
identify a sub-group with greater or lesser relative beneﬁts from
rifampicin, absolute recurrence risk varied markedly according to
this risk score, leading to NNT with rifampicin < 12 for those with
BIRDL ≥3, 15% of trial participants, compared with 26 in the whole
population. If validated, this score could therefore be used to target
rifampicin to a sub-group most likely to beneﬁt, and also pinpoint
those in whom every effort should be made to identify and remove
the infection focus. The score could also, for example, allow the
targeted, cost-effective use of positron emission tomography (PET)
to identify occult deep infection foci. 16 
Our study has several limitations. First, the trial excluded 232
patients in whom rifampicin was considered mandatory many of
whom had infected deep prosthetic devices (e.g. arterial grafts,
heart valves, joint replacements). Patients with infected devices
were not formally excluded, but the relatively small numbers of
such patients enrolled mean our ﬁndings cannot be generalised toPlease cite this article as: A. Szubert, S.L. Bailey and G.S. Cooke et al.,
Staphylococcus aureus bacteraemia: Observational analyses within the A
08.001 hose with bacteraemia associated with infected devices. 17 Second,
he relatively low mortality (15%) compared to observational co-
orts suggest those with the most severe disease may not have en-
ered the trial, which may reduce the generalisability of the ﬁnd-
ngs. Third, the small numbers of outcomes mean the multivari-
ble models should be considered exploratory given the numbers
f predictors examined and further validation is essential to inform
linical practice. 
In summary, the predictors of recurrence may be different from
hose predicting early treatment failure and death following S. au-
eus bacteraemia. This suggests these outcomes may arise from dif-
erent biological mechanisms and that combining them in a com-
osite endpoint in future trials is unlikely to be informative. 18 Ri-
ampicin reduces recurrences overall; but its impact in unselected
atients appears small compared with unmodiﬁable patient factors
nd interventions such as source control. Whilst those at highest
isk of recurrence had similar relative beneﬁts from rifampicin, this
ranslated into much greater absolute beneﬁts and hence lower
NT ( < 12). The BIRDL score might thus be able to identify those
t highest risk of recurrence and who might beneﬁt most from ri-
ampicin, but should be tested and validated prospectively in dif-
erent populations. Source control and adequate antibiotic treat-
ent durations remain essential to prevent recurrence and im-
rove outcomes from S. aureus bacteraemia. 
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